Health & Fitness
Health and Fitness
Health and Fitness
Tue, October 25, 2011
Mon, October 24, 2011
Edison Expands Cell Therapy Sector Presence with Launch of Research Coverage on Aastrom
LONDON--([ BUSINESS WIRE ])--Edison Investment Research, a UK-based independent equity research firm, announces the initiation of research coverage on Aastrom Biosciences, Inc (NASDAQ: ASTM), a US cell therapy company.
Edison has published a comprehensive report examining the investment merits of Aastrom, focusing on the potential of its lead program, ixmyelocel-T, for treating critical limb ischaemia (CLI). Ixmyelocel-T is a patient-specific cell therapy derived from bone marrow using a proprietary cell culture process. The CLI project aims to increase amputation-free survival duration in patients with blocked leg arteries. Strong Phase II data, to be fully reported 12-16 November, has led to a pivotal 594 patient Phase III starting Q411. A dilated heart indication has Phase II data with Phase IIb starting H112.
For the full report see: [ www.edisoninvestmentresearch.co.uk/research/company/aastrom-biosciences ]
The launch of coverage on Aastrom Biosciences is part of a program of research initiations on biotech companies worldwide. Edison covers over 65 biotech companies in Europe, North America and Australia. Its biotech research team has a particular focus on small- to mid-cap companies. All reports published by Edison are available to download, free of charge, from [ www.edisoninvestmentresearch.co.uk ].
Edison has pioneered a scientific detail-oriented approach to analysing companies in the biotech sector that aims to inform investors while providing a realistic assessment of the competitive strengths and threats to key drug development programs. Reports are written in a concise and non-promotional manner. All facts are carefully sourced and the analysis is underpinned by comprehensive and rigorous financial models. Edisonas reports provide an overall company valuation without any specific stock recommendation or target price.
About Edison Investment Research
Edison Investment Research is a leading international investment research company. The team of more than 75 includes over 40 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 350 companies across every sector and its research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London and Sydney and is authorised and regulated by the [ UK Financial Services Authority ]. Edison is not a US investment adviser or broker-dealer and does not provide investment advice. Edisonas reports are not solicitations to buy or sell any securities.
